Droxidopa

FDA Approved: * February 18, 2021
Pharm Company: * ZYDUS PHARMS USA INC
Category: Neurological Disorders

Droxidopa (INN; trade name Northera; also known as L-DOPS, L-threo-dihydroxyphenylserine, L-threo-DOPS and SM-5688) is a synthetic amino acid precursor which acts as a prodrug to the neurotransmitter norepinephrine (noradrenaline).[1] Unlike norepinephrine, droxidopa is capable of crossing the protective blood–brain barrier (BBB).[1] Contents 1 Medical uses 2 Side effects 3 Pharmacology 4 Chemistry 5 History 5.1 Clinical trials 6 Research 7 Reference... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Droxidopa 100 mg Oral Capsule
NDC: 0054-0532
Labeler:
Hikma Pharmaceuticals USA Inc.
Droxidopa 200 mg Oral Capsule
NDC: 0054-0533
Labeler:
Hikma Pharmaceuticals USA Inc.
Droxidopa 300 mg Oral Capsule
NDC: 0054-0534
Labeler:
Hikma Pharmaceuticals USA Inc.
Droxidopa 100 mg Oral Capsule
NDC: 0832-0720
Labeler:
Upsher-smith Laboratories, LLC
Droxidopa 200 mg Oral Capsule
NDC: 0832-0721
Labeler:
Upsher-smith Laboratories, LLC
Droxidopa 300 mg Oral Capsule
NDC: 0832-0722
Labeler:
Upsher-smith Laboratories, LLC
Droxidopa 100 mg Oral Capsule
NDC: 27241-199
Labeler:
Ajanta Pharma Limited
Droxidopa 200 mg Oral Capsule
NDC: 27241-200
Labeler:
Ajanta Pharma Limited
Droxidopa 300 mg Oral Capsule
NDC: 27241-201
Labeler:
Ajanta Pharma Limited
Droxidopa 100 mg Oral Capsule
NDC: 27808-199
Labeler:
Tris Pharma Inc

Related Brands

Drugs with the same active ingredients